– USA, DE – Incyte (Nasdaq: INCY) today announced the appointment of Dr. Otis Brawley (M.D.), as a to its Board of Directors, effective September 27, 2021.
“We are very pleased to welcome Otis to the Incyte Board of Directors. His distinguished career and extensive clinical experience will be a great addition to our Board and we expect he will contribute greatly to our continued success in the future,” said CEO, Hervé Hoppenot.
About Dr. Otis Brawley
Since 2019, Dr. Brawley has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. Before his current position at Johns Hopkins, Dr. Brawley was the Chief Medical and Scientific Officer of the American Cancer Society from 2007 to 2018, and director of the Georgia Cancer Center at Grady Memorial Hospital from 2002 to 2007. From 2001 to 2018, Dr. Brawley was also a Professor of Hematology, Oncology, Medicine and Epidemiology at Emory University. Before joining Emory, Dr. Brawley was an Assistant Director and Senior Investigator at the National Cancer Institute and an Internist and Oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital. Dr. Brawley is also a member of the boards of directors of Lyell Immunopharma, Inc. and PDS Biotechnology Corporation.
“As part of the Incyte Board, I join a very experienced and diverse team dedicated to scientific discovery and the development of new, innovative medicines for patients. I am excited about this opportunity, and look forward to participating in the leadership of this dynamic Company,” said Dr. Brawley.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics.
For more information: https://www.incyte.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.